Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis

Introduction: This retrospective study aimed to compare the efficacy and safety of transarterial chemoembolization plus lenvatinib and programmed death 1 (PD-1) inhibitors versus transarterial chemoembolization plus lenvatinib or sorafenib in patients with unresectable hepatocellular carcinoma. Meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Shu, Zhou, Minhang, Wang, Peng, Yang, Jing, Zhang, Dong, Yin, Fan, Song, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583225/
https://www.ncbi.nlm.nih.gov/pubmed/36259214
http://dx.doi.org/10.1177/15330338221133640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583225/
https://www.ncbi.nlm.nih.gov/pubmed/36259214
http://dx.doi.org/10.1177/15330338221133640

Ejemplares similares